Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B

By sjmartinez • April 2, 2024

Gebremariam T, Alkhazraji S, Gu Y, Najvar LK, Borroto-Esoda K, Patterson TF, Filler SG, Wiederhold NP, Ibrahim AS. Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B. Antimicrob Agents Chemother. 2024 Apr 1:e0154523. doi: 10.1128/aac.01545-23. Epub ahead of print. PMID: 38557112.

Tags: combination therapy, Harbor UCLA, Ibrexafungerp, infection model, Infectious Diseases, liposomal amphotericin B, mouse, mucor, mucormycosis, posaconazole, Publications, Rhizopus

When Is Enough Enough? Additional Evidence of the Power of Zero

Budoff MJ. When Is Enough Enough? Additional Evidence of the Power of Zero. Circ Cardiovasc Imaging. 2024 Dec 20:e017714. doi: 10.1161/CIRCIMAGING.124.017714. Epub ahead of print.[...]

“Anti-inflammatory Therapies in Atherosclerosis – Where are we going?”

Punnanithinont N, Kambalapalli S, Iskander B, Ichikawa K, Krishnan S, Lakshmanan S, Roy SK, Budoff M. "Anti-inflammatory Therapies in Atherosclerosis - Where are we going?".[...]

Retrospective Study of CD20 Expression Loss in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Marshalek JP, Qing X, Dragan M, Tomassetti S. Retrospective Study of CD20 Expression Loss in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. J Hematol. 2024 Dec;13(6):268-277.[...]